Related Experiment Video
Updated: Aug 1, 2026

Electrode Positioning and Montage in Transcranial Direct Current Stimulation
Published on: May 23, 2011
Prefrontal cortex modulation using transcranial direct current stimulation in opioid craving: A sham-control
Ikhlaq Ahmed1, Mohammed Qutishat2, Rima Ikhlaq3
1Central Institute of Psychiatry, Ranchi, Jharkhand, India; Birmingham and Solihull Mental Health Foundation NHS Trust, UK.
Background:
Opioid addiction, a major global health crisis, has necessitated innovative therapeutic approaches. This study aims to investigate the efficacy of Transcranial Direct Current Stimulation (tDCS) targeting the right dorsolateral prefrontal cortex (DLPFC) in reducing cravings among individuals with opioid dependence.
Method:
In this single-centre, double-blind, randomized, sham-controlled trial, 40 male inpatients with opioid dependence at the Central Institute of Psychiatry (Ranchi, India) were allocated to either active right-DLPFC tDCS (2 mA, 20 min) or sham stimulation for five consecutive days. Craving and psychosocial functioning were assessed via the Obsessive-Compulsive Drug Use Scale (OCDUS) and Addiction Severity Index (ASI) at baseline, immediately post-treatment, and at 2- and 4-week follow-ups. Repeated-measures ANOVA tested group × time differences.
Results:
At baseline, OCDUS scores did not differ between groups (Active: 32.00 ± 2.47 vs. Sham: 31.60 ± 2.85; F (1,38) = 0.582, p = 0.582, η2p = 0.015). Following treatment, the Active group showed markedly greater reductions in craving than Sham at Day 5 (10.35 ± 2.21 vs. 24.25 ± 5.29; F(1,38) = 956.5, p < 0.001, η2ₚ = 0.672) and Day 14 (6.30 ± 1.98 vs. 20.75 ± 5.22; F(1,38) = 99.56, p < 0.001, η2ₚ = 0.503), with effects maintained at Day 28 (5.75 ± 1.65 vs. 23.35 ± 6.07).
Conclusion:
Five sessions of right-DLPFC tDCS produced rapid, significant, and sustained reductions in opioid craving compared with sham, supporting its promise as an adjunctive treatment in opioid use disorder.
Related Concept Videos
Blind Procedures
Blinding
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...

